Preparation method and application of a chicken synovipositor mycoplasma nanobody with immunoprotective properties
By screening and preparing Mycoplasma synoviae nanoantibodies, the problems of short immunity period and virulence reversion of existing vaccines have been solved, achieving efficient blocking of viral invasion and early diagnosis, which is suitable for large-scale production.
Patent Information
- Application Number
- CN202610347440.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing Mycoplasma synoviae vaccines for chickens have problems such as short immunity period, need for repeated vaccination, local stress reaction and virulence reversion. Furthermore, there are no systematic reports on nanobodies in this field, making it difficult to effectively block viral invasion and achieve early diagnosis.
Chicken synoviae mycoplasma nanobodies were screened and prepared. High-affinity VHH was screened using phage display technology. Combined with yeast or prokaryotic expression systems, nanobodies with high affinity and stability were prepared for blocking viral invasion and early diagnosis.
It achieves highly efficient blocking of viral invasion by Mycoplasma synoviae in chickens, improves immune coverage, provides a rapid diagnostic tool, reduces production costs, and is suitable for large-scale production.
Smart Images

Figure CN123106894A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of molecular biology, specifically to a method for preparing and applying a mycoplasma synoviae nanobody with immunoprotective properties. Background Technology
[0002] Mycoplasma synoviae infection in chickens is a serious infectious disease caused by Mycoplasma synoviae (MS). This disease primarily causes synovitis, tenosynovitis, breast cysts, and respiratory symptoms in chickens, leading to stunted growth, increased culling rates, and decreased egg production, causing significant economic losses to the global poultry industry. MS infection can persist in flocks for a long time and is difficult to eradicate, making it one of the major pathogens restricting the healthy development of the poultry industry. Currently, MS vaccines on the market mainly include two types: inactivated vaccines and live attenuated vaccines. Inactivated vaccines require the use of mineral oil or aluminum glue adjuvants; while they have high safety, they have disadvantages such as short immunity period, the need for repeated vaccinations, and local stress reactions. Live attenuated vaccines can induce more comprehensive cellular and humoral immunity, but they have the potential for virulence reversion, synergistic pathogenicity with other mycoplasma or viruses, and are susceptible to antibiotic interference. Therefore, the development of safe, efficient, scalable, and broad-spectrum protective agents against variant strains is imperative.
[0003] Currently, subunit vaccines and corresponding diagnostic antigens targeting major adhesion proteins, membrane proteins, or metabolic enzymes of MS have become a research hotspot. However, due to the high variability of MS antigenic epitopes, the narrow immunogenicity of single recombinant proteins, and the difficulty of effectively stimulating mucosal and cellular immunity with conventional adjuvants, the field application of subunit vaccines is limited. In recent years, nanobodies have received widespread attention as novel therapeutic and diagnostic molecules. Nanobodies consist only of the heavy chain variable region (VHH), are derived from camel-dwelling heavy chain antibodies, have a molecular weight of approximately 15 kDa, and possess advantages such as high stability, low prokaryotic expression cost, strong tissue penetration, and genetic engineering capability. They can be rapidly screened through phage display, yeast display, or B cell cloning techniques. Existing studies have successfully applied nanobodies to neutralization experiments against livestock and poultry pathogens such as rotavirus, porcine epidemic diarrhea virus, and avian influenza virus, demonstrating their ability to block viral adsorption, regulate immune signals, or serve as targeted delivery vectors. However, there are currently no systematic reports on nanobodies targeting Mycoplasma synoviae in chickens. During MS infection, the pathogen first binds to the host's respiratory tract or synovial epithelial cells through its membrane surface adhesion proteins. If nanobodies targeting key adhesion proteins can be screened and obtained, they could not only directly block invasion but also be used in combination with existing vaccines to improve immunization coverage. Simultaneously, nanobodies can serve as core components of rapid diagnostic reagents, enabling early on-site detection of infection. Therefore, this study aims to establish a method for preparing Mycoplasma synoviae nanobodies based on prokaryotic expression and to systematically evaluate their in vitro neutralizing activity, animal protective effect, and diagnostic applications, providing a novel solution for comprehensive MS prevention and control. Summary of the Invention
[0004] The purpose of this invention is to provide a method for preparing and applying Mycoplasma synoviae nanobodies, in order to solve the problems mentioned in the background art, such as poor vaccine immunization effect and easy development of antibiotic resistance, and to provide a new solution for comprehensive prevention and control of MS.
[0005] One or more of the candidate VHHs selected for screening have the following characteristics: the amino acid sequence of the VHH is SEQ ID NO:1 or a variant that has more than 90% homology with SEQ ID NO:1 and retains the activity of binding to MS immunogen, or it is a conserved substitution of the CDR sequence of the VHH or an engineered derivative of the framework sequence that has been humanized and optimized for stability.
[0006] The amino acid sequence of VHH is as follows: QVQLQESGGGSVQAGGSLRLSCAASGYIASGCGMGGMGWYRQAPGKEREAVSTISRDGIRYIGSVKGRFTISQDNAKNTVYLQMNSLKPEDTAVYYCAACRRSIDDYTYWGQGTQVTVSS (SEQ ID NO: 1) The nucleotide sequence encoding the amino acid sequence of the nanobody is as follows: CAGGTCCAACTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAAACTCTCTTGTGCAGCCTCTGGTTACATTGCTAGTGGCTGGGAATGGGCGGAATGGCCTGGTACGCCAGGCTCCAGGGAAGGAGCGCGAGTTGGTTTCAACGATCAGTAGAGATGGTATCAGGTAT ATAGGCGCCGTGAAGGGCCGATTCACCATCTCCCGAGACAGCGCCAAGAACACGCTGTATCTGCAAATGTCCAGCCTGAAAACTGAGGACACGGGCGTGTATTACTGCGCGGCCTGCAGACGAATGATTGATGACTACACCTACTGGGGCCAGGGGGACCCAGGTCACCGTCTCCTCA (SEQ ID NO:2).
[0007] Preferably, the MS immunogen is a chain 2-chain 1 linked recombinant fusion protein or a conserved fragment containing a key epitope of the MS immunogen, and the epitope conformation of the recombinant protein is verified by computational structure prediction before construction to ensure that the conformation of the recombinant antigen at the key binding epitope is consistent with that of the natural MS.
[0008] This invention provides a chicken synovial mycoplasma nanobody, the amino acid sequence of which is shown in SEQ ID NO:1.
[0009] In addition, the present invention provides a chicken synovial mycoplasma nanobody, the amino acid sequence of which has more than 90% sequence identity with SEQ ID NO:1, and retains the ability to bind to MS antigen.
[0010] This invention relates to isolated nucleic acid molecules encoding nanobodies, the nucleotide sequence of which is shown in SEQ ID NO:2.
[0011] The recombinant expression vector involved in this invention comprises the aforementioned nucleic acid molecules.
[0012] The host cell involved in this invention comprises the above-described recombinant expression vector.
[0013] The host cell is a prokaryotic cell, yeast cell, insect cell, or mammalian cell. Preferably, the expression and purification include at least one or more of the following options: (1) Expressed in Escherichia coli in soluble form or as inclusion bodies and then refolded; (2) Expression in yeast or insect cells to obtain glycosylated or folded products that are closer to mammalian forms; (3) Expressed in mammalian cells to obtain products with complex modifications.
[0014] This invention relates to a method for preparing the nanobody, comprising the following steps: (a) Peripheral blood mononuclear cells from camel species immunized with MS antigen; (b) Total RNA was extracted and reverse transcribed to obtain cDNA; (c) Amplification of the VHH gene fragment using nested PCR; (d) The VHH gene fragment is cloned into a phage display vector to construct a VHH library; (e) Using MS antigen as the target, perform multiple rounds of phage panning on the VHH library; (f) Screen positive clones and sequence them to obtain the gene sequence encoding the nanobody; (g) The gene sequence is cloned into an expression vector, a His tag is introduced into the expression vector, and the nanobody is expressed and purified in a host cell.
[0015] Furthermore, the phage panning in step (e) is performed at least three times, and the titer of positive wells is higher than 1.0 × 10⁻⁶ after the third round of panning. 3 .
[0016] Preferably, the constructed VHH library is an immune-derived library; or the constructed VHH library is replaced by a synthetic library or an in vitro library designed based on a humanized and domesticated framework, in order to avoid animal immunization and improve sequence diversity.
[0017] The phage panning employs at least two different elution strategies in combination to enrich high-affinity clones. These elution strategies include: competitive elution with progressively decreasing binding strength, low-pH elution, alkaline elution, high-salt elution, and mild denaturant elution. Furthermore, a negative selection step is introduced in at least one round to remove non-specific bindings to relevant proteins and the matrix.
[0018] Preferably, a His tag is introduced into the expression vector for affinity purification or functional extension; and the resulting nanobody is subjected to chemical or enzymatic biotinylation, HRP conjugation, fluorescent labeling, or conjugation with gold nanoparticles to meet the needs of different detection platforms.
[0019] This invention relates to a nanobody construct comprising two or more of the nanobodies, wherein the nanobodies are tandemly linked by a linker peptide or fused with an Fc fragment.
[0020] Preferably, the nanobody is engineered to form a multivalent or fusion construct. The engineering modification includes: tandemly connecting two or more identical or different VHHs to form a divalent or multivalent construct, fusing with an Fc fragment to increase the in vivo half-life, or coupling with a PEG group to improve stability. The multivalent or fusion construct maintains or enhances the binding activity and neutralization and blocking ability against MS immunogens.
[0021] Preferably, the activity identification includes at least one of the following evaluation methods: (1) Blocking ELISA is used to determine the ability of nanobody flame retardant MS immunogen to bind to known antibodies or IgE; (2) Surface plasmon resonance (SPR) or biolayer interference (BLI) is used to determine the affinity constant KD; (3) Verification of the compatibility of nanobodies with actual environmental samples or clinical serum.
[0022] A kit for detecting Mycoplasma synoviae in chickens, containing the aforementioned nanobody, provides a novel solution for the comprehensive prevention and control of MS.
[0023] Preferably, the preparation method further includes using the obtained biotinylated or Avitag-labeled MS nanobody to prepare a standardized detection reagent unit. The detection reagent unit is compatible with any of the following detection platforms: blocking ELISA, indirect ELISA, streptavidin-based signal amplification system, immunochromatographic rapid detection card, electrochemical sensor or optical sensor chip. Through a modular labeling strategy, a single MS immunogen nanobody can be universally applicable and interchangeable between different platforms to achieve standardization and large-scale production of the kit.
[0024] The beneficial technical effects of this invention are: 1. The MS mycoplasma nanobody provided by this invention is a novel immunomodulator. Its unique amino acid sequence, as shown in SEQ ID NO:1, ensures high affinity binding to MS mycoplasma. Through phage display screening and ELISA verification, the high binding rate of positive clones indicates that the nanobody has excellent targeting recognition ability.
[0025] 2. The nanobody of the present invention can be efficiently expressed through a prokaryotic system such as Escherichia coli BL21(DE3), and recombinant protein with a purity of over 95% can be obtained by using inclusion body purification and refolding processes. The entire preparation process does not require complex equipment, is easy to scale up, and significantly reduces production costs. Attached Figure Description
[0026] Figure 1 This is a diagram showing the panning results of MS-specific recombinant phages in this invention; Figure 2This is an SDS-PAG diagram of Nb-Avitag fusion protein induced expression in this invention; Figure 3 This is a chromatogram showing the solubility analysis of the Nb-Avitag recombinant protein in this invention; Figure 4 This is an SDS-PAG image of the purified inclusion body Nb1-Avitag recombinant protein from this invention. Figure 5 This is a graph showing the results of verifying the activity of MS nanobodies using the ELISA method in this invention. Detailed Implementation
[0027] To more clearly illustrate the technical solution of the present invention, the present invention will be further described below with reference to the accompanying drawings. Obviously, the drawings described below are only one embodiment of the present invention. For those skilled in the art, other embodiments can be obtained based on these drawings and embodiments without creative effort, and all of them fall within the protection scope of the present invention.
[0028] Example 1, Screening of MS-specific nanobodies 1.1 Preparation of Immunogen After inactivating the MS strain, an immunogen was obtained. Glycerol-containing bacteria with the MS antigen plasmid were spread on a plate containing ampicillin resistance. After incubation for 12 h, a single colony was picked. The picked single colony, 4 mL of LB medium, and 10 μL of ampicillin were placed in a shaker and incubated at 37 ℃ and 220 r / min for 12 h to obtain a seed culture. The seed culture was inoculated into LB medium at a 1% inoculum and cultured at 37 ℃ with shaking until the OD600 value reached 0.4-0.6. Then, 0.2 mmol / L of IPTG inducer was added, and induction was performed at 37 ℃ for 6 h. 1.0 mL of the induced bacterial culture was collected, centrifuged at 12000 r / min for 1 min, and the bacterial cells were collected. 70 μL of 1× Loading Buffer was added, and the cells were dispersed by shaking. The cells were boiled in water for 10 min, then immediately placed on ice and centrifuged at 12000 r / min for 2 min. The supernatant was collected for SDS-PAGE electrophoresis to detect protein expression levels. In the SDS-PAGE electrophoresis results for detecting protein expression levels, a clear protein band appeared at a molecular weight of 26 kDa. The target protein was eluted with 6 column volumes of 1×Elute Buffer, and a small amount of the target protein was taken for electrophoretic analysis. A clear band appeared at a molecular weight of 26 kDa, with very few contaminating proteins, indicating that the expression product was well purified.
[0029] 1.2 Antigen Immunization of Alpacas 2.5 mL of MS recombinant protein was emulsified with an equal volume of 1 mg / mL 201 adjuvant and then used to immunize alpacas. Alpacas were immunized 5 times, with immunizations every two weeks after the first immunization and serum collected one week after the last immunization. The MS antibody titer in alpaca serum was detected by indirect ELISA. Serum before immunization was used as a negative control. The results showed that the serum titer was strongest after the fifth immunization, with a serum efficacy value of 256,000.
[0030] Example 2, Construction of VHH recombinant phage vector 2.1 Isolation and RNA Extraction from Alpaca Peripheral Blood Lymphocytes One week after the fifth immunization of alpacas, 10 mL of anticoagulated blood was collected using disposable blood collection tubes (containing anticoagulant). After dilution with PRMI 1640 medium, the alpaca peripheral blood lymphocytes were separated using an alpaca peripheral blood lymphocyte separation kit. The separated cells were counted using a hemocytometer, and total RNA was extracted.
[0031] 2.2 Amplification of the VHH gene fragment cDNA was synthesized using reverse transcriptase with RNA as a template, and the target gene was amplified using nested PCR. PCR primers were designed based on the upstream and downstream sequences of the alpaca VHH gene. In the first round of PCR amplification, cDNA was used as a template, and the primer sequences were as follows: F1: GAATTCATGGATAAGATGGAAGAGGTGTTGAG R1: CTCGAGCAGCTTGAACATGCCAAAGTAGGT Reaction program: 98°C, 10 sec; 55°C, 5 sec; 68°C, 10 sec; 30 cycles.
[0032] The second round of PCR amplification used the recovered products from the first round of PCR as templates to amplify the VHH gene fragment using the conserved region sequence of VHH. The primer sequences were as follows: F2: CAGGGTGCAGCTGCAGGAGTCTGGGGGAGR R2: CTAGTGCGGCCGCTGAGGAGACGGTGACCTGGGT Reaction program: 98°C, 10 sec; 55°C, 5 sec; 68°C, 10 sec; 30 cycles.
[0033] After two rounds of amplification, the PCR product was recovered, and a VHH fragment of approximately 400 bp was finally obtained. The concentration of the recovered product was 24.6 ng / μL.
[0034] 2.3 Construction of VHH phage display vectors The VHH gene fragment amplified in the second round and the vector pCANTAB 5E were digested with Pst I and Not I, and the products were ligated together with T4 DNA ligase. The ligation product was then purified using a PCR product recovery kit and eluted with sterile ultrapure water to obtain the constructed recombinant phage vector. The concentration of the recombinant phage vector was determined to be 18.9 ng / μL. The steps for recovering the enzyme digestion product are as follows: Add the collected agarose gel to Extraction Buffer at a ratio of 1:3 (100 mg: 300 μL), then incubate in a water bath at 50 ℃ until the gel melts, obtaining a gel-melted mixture. Add 500 μL of Balance Buffer to the Spin column, centrifuge at 12000 g for 1 minute, discard the liquid in the collection tube, transfer the entire gel-melted mixture to the Spin column, centrifuge at 6000 g for 1 minute, discard the liquid in the collection tube, add another 500 μL of Extraction Buffer to the Spin column, centrifuge at 12000 g for 1 minute, discard the liquid in the collection tube, then add 750 μL of Wash Buffer to the Spin column, centrifuge at 12000 g for 1 minute, discard the liquid in the collection tube, and centrifuge again at 12000 rpm for 1 minute. Finally, transfer the Spin column to a sterile 1.5 mL centrifuge tube, and add 30 μL of Wash Buffer to the Spin column. The solution in the centrifuge tube contained the target DNA fragment. The solution was then incubated in μL of sterile, enzyme-free water for 3 minutes at room temperature, and finally centrifuged at 12000 g for 1 minute.
[0035] Example 3: Harvesting of a phage antibody library 3.1 Transformation of TG1 competent cells with the ligation product TG1 competent cells were electroporated using an Eppendorf electroporator with parameters set at 2.5 kV and 5 ms. Immediately after electroporation, the electroporation cuvette was removed, and 4 mL of preheated SOC medium to 37°C was added. The electroporated competent cells were then resuspended and transferred to a sterile 50 mL centrifuge tube. This process was repeated to complete the remaining electroporation transformations. After incubation of the transformation products, 100 μL of bacterial culture was reserved for library identification. The remaining bacterial culture was evenly spread on LB / AMP-GLU plates and incubated at 37°C for 10 h. The bacterial colony was then collected using a cell scraper, and 1 / 3 volume of 50% glycerol was added. The mixture was thoroughly mixed, aliquoted, and stored at -80°C.
[0036] 3.2 Construction of phage antibody library 3.2.1 Determination of Library Capacity The bacterial culture retained after incubation of 100 μL of transformation product was diluted in 10-fold serial dilutions until the dilution was 10... -2 10 -3 10 -4 100 μL of each sample was spread onto LB / AMP-GLU plates and incubated at 37°C for 8 h. The colonies on the plates were counted, and the library capacity was estimated according to the gradient dilution ratio of the culture.
[0037] 3.2.2 Determination of Library Diversity Twenty positive clones were randomly selected and inoculated into 1 mL of culture medium for bacterial culture identification. Transformants were identified using primer F3, located approximately 341 bp upstream of the polyclonal restriction site of the pCANTAB 5E vector, and primer R2. The positive clone rate was approximately 90%. The clones identified as positive by bacterial culture PCR were sent to Shanghai Bioengineering Technology Co., Ltd. for sequencing. The sequencing results were compared using MegAlign software to identify library diversity.
[0038] The sequence of primer F3 is as follows: 5'-AATACGCAAACCGCCTCTCC-3' Example 4, Panning of MS-specific nanobodies 4.1 Rescue of the VHH phage antibody library After inoculating the phages into the culture medium and culturing them for a period of time, helper phages were used for rescue. After rescue culture, the supernatant was extracted by centrifugation, and PEG / NaCl solution was added to the supernatant for precipitation. After centrifugation, the precipitate was collected, and the precipitate was resuspended in PBS to obtain the phages. This process was used to amplify the phage library, and the successfully transformed plasmids were proliferated in large quantities to obtain a large number of phages containing the target plasmid.
[0039] 4.2 Determination of recombinant phage titer Take 20 μL of the rescued phage solution, and serially dilute it 10-fold with culture medium. Then take 100 μL of each diluted solution to obtain a 10-fold further dilution. -8 10 -9 10 -10 For the sample, add 100 μL of TG1 cells in the logarithmic growth phase, mix well, and incubate at 37°C for 15 min for infection. Spread TG1 cells infected with different dilutions of phage evenly on LB / AMP-GLU plates, incubate at 37°C for 12 h, count the colonies on the plates, and determine the titer of the amplified recombinant phage.
[0040] 4.3 Panning of MS-specific recombinant phages MS protein was coated onto the bottom of an ELISA plate, with PBS used as a negative control. Coating was performed at 4°C for 12 h. Uncoated MS protein was washed, and the plate was blocked with 1% BSA. After blocking, the blocking buffer was washed off, and a rescued VHH phage library was added. After incubation, non-specifically bound phage particles were washed off, followed by elution with triethylamine. The eluted phage particles were then used for infection propagation and titer determination. At least three rounds of washing were performed, and the titer was determined when the positive well titer was greater than 1 × 10⁻⁶ compared to the negative well titer. 3 When the time is reached, the selection is considered complete. After the third round of selection, the titer of the positive well is 1.3 × 10⁻⁶. 3 The selection results are as follows Figure 1 As shown.
[0041] 4.4 Induction of recombinant nanobody expression and acquisition of crude extract Forty-eight single colonies were picked from the ELISA plate used for the third round of titer determination and placed into wells containing 100 μL of culture medium. When the OD600 value reached approximately 0.7, they were inoculated into wells containing 1 mL of culture medium for propagation. When the OD600 value reached approximately 0.7 again, IPTG was added for induction. After culturing for 10 h, the culture was collected into 1.5 mL centrifuge tubes and subjected to three freeze-thaw cycles at -80℃. The supernatant was collected by centrifugation, which is the crude extract of soluble recombinant nanobody.
[0042] 4.5 ELISA detection of soluble recombinant nanobodies To verify the specificity of the crudely expressed nanobodies, an ELISA method was used for detection. MS mycoplasma protein was coated onto the bottom of an ELISA plate. PBS was used as a negative control, and the plate was blocked with 1% BSA. Crude nanobodies were added to each well, incubated, and then unbound nanobodies were washed away. Primary antibody was added, incubated again, and then unbound primary antibody was washed away. Secondary antibody was added, incubated again, and then unbound secondary antibody was washed away. TMB chromogenic buffer was added, incubated, and then stop buffer was added. The OD450 value was measured using an ELISA reader. Clones with positive ELISA results were selected, and the specific nanobodies were sequenced for analysis.
[0043] Example 5: Expression, purification, and activity identification of nanobodies 5.1 Construction of the prokaryotic expression vector pET-32a-Nb-Avitag The pET-32a-Nb-Avitag recombinant plasmid was synthesized based on the nanobody sequence, where the target gene is referred to as Nb-Avitag.
[0044] 5.2 Inclusion body induction and solubility identification of Nb-Avitag nanobody fusion protein The obtained recombinant plasmid was transformed into competent BL21(DE3) cells, and the positive clones were identified by PCR. The positive clones were inoculated into culture medium, and after the OD600 value reached approximately 0.7, 0.3 mM IPTG was added for induction at 37℃ for 6 h. The induced bacterial culture was collected and centrifuged. The precipitate was resuspended in PBS and sonicated. After sonication, it was centrifuged again, and the supernatant was collected and stored. The precipitate was resuspended in 1 mL PBS, and SDS-PAG analysis of Nb-Avitag fusion protein expression and solubility analysis of Nb-Avitag recombinant protein were performed. The results are as follows: Figure 2 and Figure 3 As shown, the band size is 34 kDa, and it is expressed as inclusion bodies in the precipitate. Figure 2 In the table, 1 represents expression before empty vector induction, 2 represents expression after empty vector induction, 3 represents expression before E2 induction, and 4 represents expression after E2 induction. Figure 3 In the table, 1 represents expression in empty supernatant, 2 represents expression in empty precipitate, 3 represents expression in E2 supernatant, and 4 represents expression in E2 precipitate.
[0045] 5.3 Purification of inclusion body Nb-Avitag recombinant protein The inclusion body purification method was used to purify the Nb-Avitag recombinant protein. A suitable amount of well-mixed 50% His-tag Purification Resin (denaturing formulation) was centrifuged at 4°C (1000g*10s), and the stock solution was discarded. One column volume of denaturing lysis buffer was added to the gel and mixed to equilibrate the gel. The mixture was centrifuged at 4°C (1000g*10s), and the liquid was discarded. This equilibration process was repeated 1-2 times, and the liquid was discarded. 4 mL of bacterial lysis supernatant was added to every 0.5 mL of gel (equivalent to 1 mL of 50% gel), and the gel and bacterial lysis supernatant were mixed to obtain a His-tag Purification Resin mixture. The mixture was shaken slowly at 4°C for 60 min. The mixture of lysis buffer and His-tag Purification Resin was loaded into an appropriate empty column tube. The cap at the bottom of the purification column was opened, and the liquid inside the column was allowed to flow out under gravity. 20 μL of the flow-through was collected. After all the percolation fluid had eluted, the purification column was washed five times with denaturing lysis buffer, using 1 mL of buffer each time. The first three washes, totaling 20 μL of denaturing lysis buffer, were collected. Then, the target protein was eluted eight times with denaturing elution buffer, using 1 mL of buffer each time. The eluent from each wash was collected in separate centrifuge tubes. The collected eluent was the purified His-tagged protein sample. Finally, the ready-to-use 3.5 kDa dialysis bag was thoroughly rinsed with ultrapure water. Results are as follows: Figure 4As shown, after purification, most of the impurities in the Nb-Avitag recombinant protein were removed, and the target protein showed the elution peak at 3 mL. Figure 4 In the sample, 1 is bacterial lysis buffer, 2 is sample loading buffer, 3 is the first mL of denaturing lysis buffer, 4 is the second mL of denaturing lysis buffer, 5 is the third mL of denaturing lysis buffer, 6 is the first mL of denaturing wash buffer, 7 is the second mL of denaturing wash buffer, 8 is the third mL of denaturing wash buffer, 9 is the first mL of denaturing elution buffer, 10 is the second mL of denaturing elution buffer, 11 is the third mL of denaturing elution buffer, 12 is the fourth mL of denaturing elution buffer, 13 is the fifth mL of denaturing elution buffer, and 14 is the sixth mL of denaturing elution buffer.
[0046] 5.4 Refolding of Nb-Avitag recombinant protein After thoroughly rinsing the ready-to-use 3.5 kDa dialysis bag with ultrapure water, the denatured and purified Nb1-Avitag recombinant protein was added to the dialysis bag. Dialysis was performed sequentially at 4°C using 6M, 4M, 2M, and 0M urea dialysate solutions, changing the dialysate every 12 hours. Finally, after dialysis in 0M urea dialysate, the dialysis bag was dialyzed twice in PBS. The dialysis buffer consisted of: Tris 180 mM, NaCl 200 mM, EDTA·2Na 20 mM, Glycine 5%, Glycerol 40%, Oxidized glutathione 1.9 mM, Reduced glutathione 30 mM, and urea (6M, 4M, 2M, 0M). The pH of the dialysis buffer was 8.2.
[0047] 5.5 Biotinylation of Nb-Avitag fusion protein The Nb-Avitag fusion protein was incubated for 60 min at 30°C using a 25 μL biotinylation system. The biotinylation system consisted of: 10× Biotin Ligase Buffer A (2.5 μL, final concentration 1×), 10× Biotin Ligase Buffer B (2.5 μL, final concentration 1×), Biotin Ligase (0.17 μL, final concentration 6.4 ng / μL), dialyzed Nb-Avitag (1 nmol, final concentration 40 μM), and the remainder sterile, enzyme-free water.
[0048] 5.6 ELISA method to verify MS nanobody activity MS-Nb activity was verified using ELISA. MS protein was coated onto an ELISA plate. Unbound MS protein was washed away with PBST. 100 μL of 1% BSA was added to each well for blocking. After incubation, the blocking buffer was washed away. Diluted nanobody was added, and after incubation, unbound nanobody was washed away. Empty vector-lysed bacterial culture was diluted as a negative control, and PBS was used as a blank control. The plates were incubated at 37°C for 1 h, washed 5 times with PBST, and then enzyme-labeled secondary antibody was added. The plates were incubated at 37°C for 1 h, washed 5 times with PBST, and then TMB chromogenic buffer was added. After incubation, stop solution was added, and the OD450 value of each well was measured using an ELISA reader. Results are as follows: Figure 5 The above states that a coating concentration greater than 0.25 is sufficient to determine a positive result.
[0049] The above embodiments are merely exemplary embodiments of the present invention and are not intended to limit the present invention. The scope of protection of the present invention is defined by the claims. Those skilled in the art can make various modifications or equivalent substitutions to the present invention within the scope of its essence and protection. Such modifications or equivalent substitutions should also be considered as falling under the protection of the present invention.
Claims
1. A chicken synoviae mycoplasma nanobody with immunoprotective properties, characterized in that, Its amino acid sequence is shown in SEQ ID NO:
1.
2. A chicken synoviae nanoantibody with immunoprotective properties, characterized in that, Its amino acid sequence has more than 90% sequence identity with SEQ ID NO:1, and it retains the ability to bind to MS antigen.
3. A nucleic acid molecule encoding the nanobody according to any one of claims 1-2.
4. The nucleic acid molecule according to claim 3, characterized in that, Its nucleotide sequence is shown in SEQ ID NO:
2.
5. A recombinant expression vector, characterized in that, It includes the nucleic acid molecule as described in claim 3 or 4.
6. A host cell, characterized in that, It includes the recombinant expression vector as described in claim 5.
7. The host cell according to claim 6, characterized in that, The host cell can be a prokaryotic cell, yeast cell, insect cell, or mammalian cell.
8. A method for preparing the nanobody according to any one of claims 1-2, characterized in that, Includes the following steps: (a) Peripheral blood mononuclear cells from camel species immunized with MS antigen; (b) Total RNA was extracted and reverse transcribed to obtain cDNA; (c) Amplification of the VHH gene fragment using nested PCR; (d) The VHH gene fragment is cloned into a phage display vector to construct a VHH library; (e) Using MS antigen as the target, perform multiple rounds of phage panning on the VHH library; (f) Screen positive clones and sequence them to obtain the gene sequence encoding the nanobody; (g) The gene sequence is cloned into an expression vector, a His tag is introduced into the expression vector, and the nanobody is expressed and purified in a host cell.
9. A nanobody construct, characterized in that, The nanobody comprises two or more of the nanobodies according to any one of claims 1-2, wherein the nanobodies are tandemly linked by a linker peptide or fused with an Fc fragment.
10. A kit for detecting Mycoplasma synoviae in chickens, characterized in that, It includes the nanobody as described in any one of claims 1-2.
